Abstract
Objective
To investigate the effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the secretion of vascular endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMCs) and on the generation of reactive oxygen species (ROS) by leukocytes.
Methods
PBMCs and leukocytes were obtained from venous blood samples collected from 20 healthy individuals. VEGF secretion was evaluated using a commercial ELISA kit, while ROS production was determined using a luminol-dependent chemiluminescence assay.
Results
Rosiglitazone and calphostin C (a protein kinase C inhibitor) inhibited VEGF secretion by PBMCs by 63.7 and 62.3%, respectively. Both agents reduced ROS production in non-stimulated human leukocytes and down-regulated the enhanced generation of ROS in leukocytes that had been stimulated with the PKC activator phorbol 12,13-dibutyrate.
Conclusion
The results support the involvement of PKC as a direct, and/or NADPH-oxidase as an indirect, target for the action of rosiglitazone on VEGF secretion by PBMCs and ROS production in human leukocytes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR gamma activation in human endothelial cells increases plasminogen activator inhibitor type 1 expression: PPAR gamma as a potential mediator in vascular disease. Aterioscler Throm Vasc Biol. 1999;19:546–51.
Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274:9116–21.
Park BC, Thapa D, Lee JS, Park SY, Kim JA. Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells. J Pharmacol Sci. 2009;111:1–12.
Panigraphy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923–32.
Ushio-Fukai M, Tang Y, Fukai T, Dikalov S, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW. Novel role of gp91phox-containing NADPH oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Cir Res. 2002;91:1160–7.
Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, Dikalov SI, Chen YE, Tojo T, Fukai T, Fujimoto M, Patrushev NA, Wang N, Kontos CD, Bloom GS, Alexander RW. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Cir Res. 2004;95:276–83.
Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patruschev N, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005;111:2347–55.
Lasségue B, Cempus RE. Vascular NAD(P)H oxidases: specific features, expression and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277–97.
Bicalho HMS, Gontijo MC, Nogueira-Machado JA. Simple technique for simultaneous human leukocytes separation. J Immunol Methods. 1981;40:115–6.
Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Tends Cell Biol. 2001;11:S37–43.
Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61–6.
Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE. 2001;112:21.
Kroll J, Waltenberg J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272:32521–7.
Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinases-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res. 2003;92:e80.
Kim HJ, Woo IS, Kang ES, Eun SY, Kim GH, Ham SA, Kim HJ, Lee JH, Chang KC, Kim JH, Lee HT, Seo HG. Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPAR gamma in A549 cells. Biochem Biophys Res Commun. 2006;349:660–7.
Guo W, Xie W, Han J. Modulation of adipocyte lipogenesis by octanoate: involvement of reactive oxygen species. Nutr Metab. 2006;3:30.
Kamata Y, Iwamato M, Muroi K, Minota S. Repeated local implantation of autologous peripheral blood mononuclear cells for the treatment of ischaemic digits in patients with connective tissue diseases. Rheumatology. 2011;50:906–10. doi:10.1093/rheumatology/keq389.
Acknowledgments
The authors wish to thank the Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) and the Coordenação de Aperfeiçoamento de Pessoal de Nivel Superior (CAPES) for financial support.
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Liwu Li.
Rights and permissions
About this article
Cite this article
Mattos, R.T., Bosco, A.A. & Nogueira-Machado, J.A. Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes. Inflamm. Res. 61, 37–41 (2012). https://doi.org/10.1007/s00011-011-0386-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-011-0386-6